Only recently, anti-IL6R tocilizumab proved its efficacy in GCA, although only around 55–85% patients achieved complete and long-term disease remission while on this treatment [35,36], and not all patients can successfully discontinue glucocorticoids [37]. Here, IL6R is linked to temporal arteritis.